Pfizer, Inc. (NYSE:PFE) has been given a consensus rating of “Hold” by the twenty-three ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $37.63.
PFE has been the subject of a number of analyst reports. Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. ValuEngine cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Morgan Stanley reaffirmed a “neutral” rating and set a $35.00 price objective (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Jefferies Group LLC reaffirmed a “neutral” rating and set a $34.00 price objective on shares of Pfizer in a research note on Friday, June 16th. Finally, BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd.
Shares of Pfizer (PFE) traded up 0.32% during midday trading on Thursday, hitting $34.10. The stock had a trading volume of 15,442,446 shares. The firm’s 50-day moving average price is $33.36 and its 200-day moving average price is $33.49. Pfizer has a one year low of $29.83 and a one year high of $34.75. The firm has a market capitalization of $202.80 billion, a PE ratio of 24.95 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts predict that Pfizer will post $2.56 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a $0.32 dividend. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.75%. Pfizer’s dividend payout ratio (DPR) is 94.12%.
TRADEMARK VIOLATION WARNING: This report was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.truebluetribune.com/2017/09/17/brokerages-set-pfizer-inc-pfe-pt-at-37-63.html.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 124,774 shares in the company, valued at $4,242,316. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 426,291 shares of company stock worth $14,475,911. Corporate insiders own 0.06% of the company’s stock.
Several institutional investors have recently modified their holdings of PFE. Vanguard Group Inc. raised its holdings in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Franklin Resources Inc. raised its holdings in Pfizer by 0.9% during the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after acquiring an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Pfizer by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Pfizer by 3.9% during the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after acquiring an additional 1,275,832 shares in the last quarter. Finally, LSV Asset Management raised its holdings in Pfizer by 0.6% during the second quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock worth $1,117,726,000 after acquiring an additional 199,100 shares in the last quarter. Institutional investors own 69.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.